Reflection of modern concepts of therapy in the treatment of allergic diseases of the nose and paranasal sinuses

The article highlights the urgent problem of modern medicine - allergic diseases. Over the past decades, there has been a significant increase in the prevalence of this pathology, the share of which in the general structure of the incidence of the population remains high to this day. The statistics are staggering. According to various sources, various manifestations of allergies affect from 10% to 40% of the world’s population. According to conservative estimates, more than 500 million people in the world. According to epidemiological studies, the amount of atopy is growing by 5-6% every year. The disease has a huge impact on the quality of life of the patient. Needless to say, an allergic disease can be accompanied by complications, including life-threatening. The big financial burden on the budget of our country is the economic costs of combating allergies and its complications. Therefore, the treatment of this nasology is one of the key issues both in the global and in Russian healthcare.

Intranasal (topical) corticosteroids (IKS) are the drug of choice in the treatment of patients diagnosed with allergic rhinitis (AR). However, ICS are widely used in clinical practice and in the treatment of other diseases of the nose and paranasal sinuses. Depending on the nature of the pathological process, the duration of the drug can vary widely: from two weeks to several months or years. The purpose of this work is to systematize relevant publications and analyze possible uses for this group of drugs. The article reflects the issues of epidemiology, etiopathogenesis of allergic rhinitis. Consistently considered modern methods of treatment, in particular the use of (ICS) in therapy regimens. The results of international multicenter randomized controlled clinical trials are presented, the purpose of which was to determine and evaluate the efficacy and tolerability of ICS, in particular fluticasone propionate. It is concluded that fluticasone propionate is a modern and effective agent for the pathogenetic treatment of patients with not only allergic but also non-allergic rhinitis and can be recommended in the modern treatment regimen for both allergic and non-allergic rhinitis.

1. Kozulina I.E., Kurbacheva O.M., Il`ina N.I. Allergy today. Analysis of new epidemiological data. Rossijskij allergologicheskij zhurnal = Russian Journal of Allergy. 2014;(3):3–10. (In Russ.) Available at: http://rusalljournal.ru/sc/pdf/3-2014.pdf

2. Guryanova S.V. Integrated approaches in diagnistics and therapy of allergic diseases. Vestnik RUDN. Seriya: Meditsina = RUDN. Journal of Medicine. 2018;22(1):75–85. doi: 10.22363/2313-0245-2018-22-1-75-85.

3. Eder W., Ege M.J., von Mutius E. The Asthma Epidemic. N Engl J Med. 2006;355(21):2226–2235. doi: 10.1056/NEJMra054308.

4. Barnes P., Drazen J., Rennard S., Thomson N. (ed.). Asthma and COPD: Basic Mechanisms and Clinical Management. 2nd ed. Elsevier; 2009. 896 p. doi: 10.1016/B978-0-12-374001-4.X0001-6.

5. Ryazancev S.V. Allergic rhinitis – etiology, pathogenesis, pharmacotherapy features. Methodological recommendations. Saint Petersburg: Nacional’nyj registr lecheniya sinusitov; 2006: 28. (In Russ.) Available at: https://nikio.ru/wp-content/uploads/2016/07/%D0%90%D0%9B%D0%9B%D0%95%D0 %A0%D0%93%D0%98%D0%A7%D0%95%D0%A1%D0%9A%D0%98%D0%99-%D0%A0%D0%98%D0%9D%D0%98%D0%A2.pdf.

6. Lopatin A.S. Clinical guidelines for the diagnosis and treatment of allergic rhinitis: a manual for physicians. Saint-Petersburg: RIA:AMI; 2004. 48 p. (In Russ.)

7. Kozulina I.E., Kurbacheva O.M. One again about allergy: Epidemiology and the essentials of pathogenesis, diagnosis, and therapy. Rossijskaya rinologiya = Russian Rhinology. 2014;22(4):46–50. (In Russ.) doi: 10.17116/rosrino201422446-50.

8. Van Cauwenberge P., Bachert C., Passalacqua G., Bousquet J., Canonica G.W., Durham S.R. et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55(2):116–134. doi: 10.1034/j.1398-9995.2000.00526.x.

9. Lack G. Pediatric allergic rhinitis and comorbid disorders. The Journal of Allergy and Clinical Immunology. 2001;108(1):9–15. doi: 10.1067/mai.2001.115562.

10. Peshikova M.V., Lebedev N.E., Tetel’baum O.V. Ways to improve of the diagnostics of the allergic rhinitis in children. Pediatricheskij vestnik Yuzhnogo Urala = Pediatric Bulletin of the South Ural. 2015;(2):39–45. (In Russ.) Available at: http://xn–74-dlcmpmt5aj.xn–p1ai/vestnik/v2015_2.pdf.

11. Min Y.G. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy, Asthma and Immunology Research. 2010;2:65–76. doi: 10.4168/aair.2010.2.2.65.

12. Yanov YU.K., Ryazancev S.V., Artyushkin S.A., Fanta I.V., Pavlova S.S. Аllergic rhinitis: the modern aspects of therapy. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2018;83(3):56–60. (In Russ.) doi: 10.17116/otorino201883356.

13. Stone K.D., Prussin C., Metcalfe D.D. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2):73–80. doi: 10.1016/j.jaci.2009.11.017.

14. Bradding P., Roberts J.A., Britten K.M., Montefort S., Djukanovic R., Mueller R. et al. Interleukin-4, -5, and -6 and tumor necrosis factor alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994;10(5):471–480. doi: 10.1165/ajrcmb.10.5.8179909.

15. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(86):8–160. doi: 10.1111/j.1398-9995.2007.01620.x.

16. Radtsig E.Yu., Varavina M.A., Radtsig A.N. Differential diagnosis and treatment of allergic rhinitis from the viewpoint of European consensuses Rossijskaya otorinolaringologiya = Russian Otorhinolaryngology. 2018;(5):73– 81. (In Russ.) doi: 10.18692/1810-4800-2018-5-73-81.

17. Roberts G., Xatzipsalti M., Borrego L.M., Custovic A., Halken S., Hellings P.W. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102–1116. doi: 10.1111/all.12235.

18. Bousquet J., Schunemann H.J., Zuberbier T., Bachert C., Baena-Cagnani C.E., Bousquet P.J. Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. Allergy. 2010;65(10):1212–1221. doi: 10.1111/j.1398-9995.2010.02439.x.

19. Il’ina N.I. (ed.), Kurbacheva O.M., Pavlova K.S., Pol’ner S.A. Allergic rhinitis. Clinical recommendations. 2013. (In Russ.) Available at: http://nrcii.ru/ docs/2.allergic_rhinitis.pdf.

20. Sidorenko I.V. Allergic rhinitis. Meditsinskiy sovet = Medical Counci. 2007(1):10–15. (In Russ.) Available at: http://www.medlinks.ru/article.php?sid=31680.

21. Greiff L., Andersson M., Svensson C., Persson C.G. Topical azelastine has a 12-hour duration of action as assessed by histamine challenge-induced exudation of _2-macroglobulin into human nasal airways. Clin Exp Allergy. 1997;27(4):438–444. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9146938.

22. Korsgren M., Andersson M., Larsson L., Aldén-Raboisson M., Greiff L. Onset of action of a topical antihistamine as assessed by histamine challenge– induced plasma exudation responses. Ann Allergy Asthma Immunol. 2006;96(2):345–348. doi: 10.1016/S1081-1206(10)61246-X.

23. Svensson C., Baumgarten C.R., Pipkorn U., Alkner U., Persson C.G. Reversibility and reproducibility of histamine induced plasma leakage in nasal airways. Thorax. 1989;44(1):13–18. doi: 10.1136/thx.44.1.13.

24. Havle A., Jain V., Ahmed M.F., Shedge S., Dokania V., Bagwe V. Olopatadine Hydrochloride and Fluticasone Propionate in Topical Treatment of Allergic Rhinitis: A Single Blind Randomised Study. J Clin Diagn Res. 2016;10(12):MC04–MC07. doi: 10.7860/JCDR/2016/20810.9120.

25. Crim C., Pierre L.N., Daley-Yates P.T. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther. 2001;23(9):1339–1354. doi: 10.1016/S0149-2918(01)80113-2.

26. Fardon T.C., Lee D.K.C., Haggart K., McFarlane L.C., Lipworth B.J. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med. 2004;170(9):960–966. doi: 10.1164/rccm.200404-500OC.

27. Roberts G., Xatzipsalti M., Borrego L.M., Custovic A., Halken S., Hellings P.W. et al. Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2013;68(9):1102–1116. doi: 10.1111/all.12235.

28. Tayab Z.R., Fardon T.C., Lee D.K.C., Haggart K., McFarlane L.C., Lipworth B.J. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol. 2007;64(5):698–705. doi: 10.1111/j.1365-2125.2007.02919.x.

29. Bernstein D.I., Levy A.L., Hampel F.C., Baidoo C.A., Cook C.K., Philpot E.E., Rickard K.A. Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy. 2004;34(6):952–957. doi: 10.1111/j.1365-2222.2004.01952.x.

30. Ratner P., Van Bavel J., Mohar D., Jacobs R.L., Hampel F., Howland W., Karwal R. Efficacy of daily intranasal fluticasone propionate on ocular symptoms associated with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2015;114(2):141–147. doi: 10.1016/j.anai.2014.11.012.

31. Hadley J.A., Derebery J.M., Marple B.F. Comorbidities and allergic rhinitis: not just a runny nose. J Fam Pract. 2012;61(2):11–15. Available at: https://www.ncbi.nlm.nih.gov/pubmed/22312619.